Preparation containing hepatocyte growth-promoting factor and preparation method thereof
By using L-arginine and phosphate regulators in hepatocyte-promoting auxin preparations and adjusting the freeze-drying process, the problems of unstable product quality and high energy consumption are solved, and more stable preparation production and production costs are achieved. .
Patent Information
- Application Number
- CN202410853583.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-27
- Publication Date
- 2024-11-08
AI Technical Summary
The existing hepatocyte-promoting auxin preparations are in a non-dry state before freeze-drying, resulting in unstable product quality. Some drugs are adsorbed by activated carbon. The pH regulators cause a large difference in the pH value of the drug liquid and the pH value after lyophilization, which affects the polypeptide drugs. Stability, long lyophilization time leads to high energy consumption and high production costs.
Using L-arginine as an auxiliary material, adjust the order of adding activated carbon, use phosphoric acid or sodium phosphate to adjust the pH value, improve the freeze-drying process, shorten the freeze-drying time, and quickly get out of the non-drying state through pre-freezing and secondary drying to ensure hepatocyte-promoting The stability of auxin.
It improves the stability of hepatocyte-promoting auxin, avoids the content reduction caused by activated carbon adsorption, maintains the consistency of the pH value of the medicine liquid, shortens the lyophilization time, and reduces energy consumption and production costs.
Smart Images

Figure BDA0004917615850000081 
Figure BDA0004917615850000091
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and specifically relates to a preparation containing hepatocyte growth promoting factor and a preparation method thereof. Background Art
[0002] Hepatocyte growth factor is a small molecule polypeptide active substance extracted and purified from fresh suckling pig or cow liver. It can significantly stimulate the DNA synthesis of new liver cells, promote the recovery of damaged liver cell mitochondria and rough endoplasmic reticulum, promote liver cell regeneration, accelerate liver tissue repair, and restore liver function; it can improve the phagocytic function of liver Kupffer cells, prevent further damage to liver cells by toxins from the intestine, and inhibit the activity of tumor necrosis factor (TNF) and Na + , K + -ATPase activity inhibitor, thereby promoting the repair of liver necrosis, while reducing transaminase, serum bilirubin and shortening prothrombin time; it has a good protective effect on carbon tetrachloride-induced liver cell damage; it has a significant effect on improving survival of liver failure induced by D-galactosamine. It can be used for the adjuvant treatment of various severe viral hepatitis (early or mid-stage acute, subacute, chronic severe hepatitis).
[0003] The freeze-dried preparation of hepatocyte growth factor for injection is a sterile freeze-dried product of hepatocyte growth factor plus a suitable freeze-drying protective agent, which is a white or off-white freeze-dried block or powder. Its existing production process is: preparation of liquid medicine - filling and half-stoppering - freeze drying, plugging - capping - visual inspection - packaging; specifically: weigh the prescribed amount of mannitol and dextran and dissolve them in 50% of the total preparation amount of water for injection, measure the prescribed amount of hepatocyte growth factor solution and add it to the batching tank, then make up the volume with water for injection and stir well. Use a pH adjuster to adjust the pH value to 6.0-7.0 (pH adjuster: 5% NaOH solution or 5% HCl solution). Then add 1‰ (g / ml) activated carbon, let it stand for 30 minutes, and filter to remove carbon. Filter with a sterilizing filter and set aside. Take the above-mentioned refined filtrate and divide it into 10ml tube bottles at 2ml per bottle. The tube bottles are placed on the plate layer of the freeze dryer product room, pre-freeze for 2 hours to -40℃ and keep warm for 4 hours, turn on the water trap refrigeration switch, and after the insulation is completed, turn on the vacuum pump. When the vacuum pump reading drops below 20 Pa, gradually increase the plate temperature to -5℃, keep warm for 14 hours, increase the temperature to 0℃ and continue to keep warm for 5 hours. When the product temperature is close to the plate temperature, continue to increase the plate temperature to 30℃ and keep warm for more than 5 hours. When the product temperature is close to the plate temperature again, terminate the freeze-drying, vacuum cover, press plug and package.
[0004] The existing preparation method has the following disadvantages: the hepatocyte growth factor is in a non-drying state from the time of filling to the end of freeze drying, and the product quality is unstable; while filtering and decarbonizing, part of the hepatocyte growth factor is also adsorbed, thereby reducing the content; 5% HCl solution or 5% NaOH solution is used as a pH regulator, and the pH value of the drug solution is quite different from the pH value of the product after freeze drying and then re-dissolving, and in the strong acid and strong base HCl or NaOH solution, the stability of the polypeptide biochemical drug is affected, which is easy to cause the content to decrease; during the freeze drying process, the freeze drying time exceeds 30 hours, the freeze drying time is long, the hepatocyte growth factor is in a non-drying state for a long time, and the product quality is unstable; at the same time, the freeze drying time is long, the energy consumption is large, and the production cost is high. Summary of the invention
[0005] In order to overcome the above problems existing in the prior art, the present invention provides a preparation containing hepatocyte growth promoting factor and a preparation method thereof.
[0006] The first aspect of the present invention provides a preparation containing hepatocyte growth promoting factor, comprising the following ingredients: hepatocyte growth promoting factor and L-arginine.
[0007] According to some embodiments of the preparation of the present invention, the preparation includes the following ingredients in parts by weight: 200-800 parts of hepatocyte growth factor, for example, 200 parts, 250 parts, 300 parts, 360 parts, 410 parts, 430 parts, 480 parts, 530 parts, 620 parts, 710 parts, 780 parts, and 800 parts; 0.005-0.02 parts of L-arginine, for example, 0.005 parts, 0.008 parts, 0.01 parts, 0.015 parts, 0.018 parts, and 0.02 parts.
[0008] According to some embodiments of the preparation of the present invention, the hepatocyte growth promoting factor is an aqueous solution of a biologically active polypeptide extracted from the fresh liver of a healthy suckling pig or a non-lactating newborn calf.
[0009] According to some embodiments of the formulation of the present invention, the formulation further comprises an excipient and water.
[0010] According to some embodiments of the preparation of the present invention, the weight proportion of the excipient in the preparation is 100-300 parts, for example, 100 parts, 120 parts, 150 parts, 180 parts, 200 parts, 220 parts, 250 parts, 280 parts, 300 parts.
[0011] According to some embodiments of the preparation of the present invention, the weight parts of water in the preparation are 10000-30000 parts, for example, 10000 parts, 11000 parts, 12000 parts, 13000 parts, 15000 parts, 18000 parts, 20000 parts, 25000 parts, 30000 parts.
[0012] According to some embodiments of the formulation of the present invention, the excipient is mannitol.
[0013] According to some embodiments of the formulation of the present invention, the water is water for injection.
[0014] The second aspect of the present invention provides a method for preparing the preparation according to the first aspect of the present invention, comprising the following steps:
[0015] (1) heating a mixed solution containing an excipient, activated carbon and water, and filtering and removing carbon after heating is completed to obtain a first solution;
[0016] (2) Mixing the first solution, L-arginine and the aqueous solution containing hepatocyte growth promoting hormone to obtain a mixed solution, adjusting the pH of the mixed solution, filtering to obtain a semi-finished product, and freeze-drying the semi-finished product to obtain a preparation containing hepatocyte growth promoting hormone.
[0017] According to some embodiments of the preparation method of the present invention, in step (1), the weight ratio of the activated carbon to the excipient is 1:(8-12), for example 1:8, 1:9, 1:10, 1:12.
[0018] According to some embodiments of the preparation method of the present invention, in step (1), the weight ratio of the excipient to water is 1:(100-300), for example 1:100, 1:110, 1:120, 1:135, 1:150, 1:160, 1:210, 1:220, 1:260, 1:280, 1:300.
[0019] According to some embodiments of the preparation method of the present invention, in step (1), the heating is to heat the mixed solution to boiling and keep boiling for 10-20 minutes, for example, 10 minutes, 12 minutes, 15 minutes, 18 minutes, 20 minutes.
[0020] According to some embodiments of the preparation method of the present invention, in step (2), the water temperature of the aqueous solution containing hepatocyte growth factor is ≤25°C, for example, 24°C, 20°C, 18°C, 16°C, 10°C, preferably 10-20°C.
[0021] According to some embodiments of the preparation method of the present invention, the water temperature of the aqueous solution containing hepatocyte growth promoting factor is 2-10°C.
[0022] According to some embodiments of the preparation method of the present invention, in step (2), the weight ratio of the hepatocyte growth factor to water in the aqueous solution containing the hepatocyte growth factor is (2-3):100, for example, 2:100, 2.5:100, 3:100.
[0023] According to some embodiments of the preparation method of the present invention, in step (2), after obtaining the mixed solution, water is added to the mixed solution to make up the volume to the total amount.
[0024] According to some embodiments of the preparation method of the present invention, adjusting the pH of the mixed solution is to adjust its pH value to 6.0-7.0.
[0025] According to some embodiments of the preparation method of the present invention, phosphoric acid and / or sodium phosphate are used to adjust the pH of the mixed solution.
[0026] According to some embodiments of the preparation method of the present invention, a phosphoric acid aqueous solution with a mass concentration of 3%-10% is used to adjust the pH of the mixed solution, for example, 3%, 5%, 8%, 10%.
[0027] According to some embodiments of the preparation method of the present invention, a sodium phosphate aqueous solution with a mass concentration of 3%-10% is used to adjust the pH of the mixed solution, for example, 3%, 5%, 8%, or 10%.
[0028] According to some embodiments of the preparation method of the present invention, in step (2), the filtration is performed using a sterilizing filter.
[0029] According to some embodiments of the preparation method of the present invention, the pore size of the sterilizing filter is 0.2-0.3 μm, for example, 0.2 μm, 0.25 μm, 0.28 μm, 0.3 μm.
[0030] According to some embodiments of the preparation method of the present invention, the freeze-drying includes pre-freezing at a temperature ≤-35°C, performing a primary drying at a temperature of 5 to -5°C after the pre-freezing is completed, and performing a secondary drying at a temperature of 12°C-30°C after the primary drying is completed.
[0031] The stability of hepatocyte growth factor can be ensured by increasing the pre-freezing speed, rapidly freezing the intermediate product to below the eutectic point, and shortening the freeze-drying time so that the hepatocyte growth factor can be removed from the non-dry state as soon as possible.
[0032] According to some embodiments of the preparation method of the present invention, the pre-freezing time is 2-5 hours, for example, 2 hours, 3 hours, 4 hours, 5 hours.
[0033] According to some embodiments of the preparation method of the present invention, the vacuum degree of the primary drying is ≤10Pa, for example, 10Pa, 8Pa, 6Pa, 5Pa.
[0034] According to some embodiments of the preparation method of the present invention, the primary drying time is 5-8 hours, for example, 5 hours, 6 hours, 7 hours, or 8 hours.
[0035] According to some embodiments of the preparation method of the present invention, the secondary drying includes two stages, and the drying temperature of the first stage is 10-15°C, such as 10°C, 12°C, 13°C, 15°C.
[0036] According to some embodiments of the preparation method of the present invention, the vacuum degree of the first stage is 10-15Pa, for example, 10Pa, 12Pa, 14Pa, 15Pa.
[0037] According to some embodiments of the preparation method of the present invention, the drying time of the first stage is 1-2 hours, for example, 1 hour, 1.5 hours, 2 hours.
[0038] According to some embodiments of the preparation method of the present invention, the second stage drying temperature of the secondary drying is 25-35°C, for example, 25°C, 28°C, 30°C, 32°C, 35°C.
[0039] According to some embodiments of the preparation method of the present invention, the vacuum degree of the second stage is 10-15Pa, for example, 10Pa, 12Pa, 14Pa, 15Pa.
[0040] According to some embodiments of the preparation method of the present invention, the drying time of the second stage is 3-5 hours, for example, 3 hours, 3.5 hours, 4 hours, 4.5 hours.
[0041] According to some embodiments of the preparation method of the present invention, the heating time between two adjacent drying processes is 50-70 min, for example, 50 min, 55 min, 60 min, 65 min, 70 min.
[0042] The present invention shortens the freeze-drying time from more than 30 hours to 16-20 hours by improving the freeze-drying process.
[0043] According to some embodiments of the preparation method of the present invention, the freeze-drying implementation equipment is a freeze dryer.
[0044] According to some embodiments of the preparation method of the present invention, before the semi-finished product enters the freeze dryer, the temperature of the freeze dryer is pre-lowered to ≤-45°C, such as -45°C, -50°C, or -55°C.
[0045] According to some embodiments of the preparation method of the present invention, after the semi-finished product enters the freeze dryer, the plate temperature of the freeze dryer is reduced to ≤-35°C, such as -35°C, -38°C, or -40°C within 30-60 minutes.
[0046] According to some embodiments of the preparation method of the present invention, the preparation method comprises the following steps:
[0047] (1) Prefreezing: First, the temperature of the freeze dryer condenser is pre-lowered to below -45°C. After the semi-finished product enters the freeze dryer, the temperature of the freeze dryer plate layer is quickly lowered to below -35°C within 1 hour (after the semi-finished product is qualified, 1 ml is divided into 2 ml vials, 2 ml is divided into 5 ml vials, and 3 ml is divided into 10 ml vials, and the vials are placed on the plate layer of the freeze dryer sample room to wait for freeze drying). The low temperature state is maintained for 2.5 hours;
[0048] (2) Primary drying: Turn on the vacuum pump, keep the vacuum degree of the freeze drying chamber below 10Pa, raise the temperature to 0°C within 1 hour, keep the temperature for 5-8 hours, and perform primary drying;
[0049] (3) Secondary drying: After the semi-finished product is dried once, the plate layer is heated to 12°C within 1 hour (the vacuum degree is controlled at 10-15 Pa) and kept warm for 1-2 hours, then heated to 30°C for 1 hour and kept warm for 3.5 hours (the total freeze-drying time is 16-20 hours).
[0050] (4) During the freeze-drying process, check the plate layer temperature, semi-finished product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0051] The beneficial effects of the present invention include:
[0052] 1. The L-arginine auxiliary material selected in the preparation process of the present invention protects the stability of hepatocyte growth promoting factor.
[0053] 2. The preparation of the present invention adjusts the order of adding activated carbon during the preparation process, thereby avoiding the problem of reduced content of hepatocyte growth factor due to adsorption of activated carbon. The present invention also adjusts the pH regulator so that the pH value of the preparation is consistent with the pH value of the drug solution after freeze-drying and re-dissolving the product, thereby making the product quality more stable.
[0054] 3. The freeze-drying process used in the preparation method of the present invention has a shorter freeze-drying time, which shortens the time that the hepatocyte growth factor is in a non-dried state, and further ensures the stability of the hepatocyte growth factor.
[0055] 4. The preparation method of the preparation of the present invention has low energy consumption, which can reduce energy consumption by about 35%. At the same time, without increasing hardware investment, the production capacity can be increased by about 35%, thereby reducing production costs. DETAILED DESCRIPTION
[0056] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0057] Example 1
[0058] Batch number 211216; production volume 10,000 bottles.
[0059] 1.1 Prescription: 200g of hepatocyte growth hormone; 5mg of L-arginine; 100g of mannitol; add water for injection to 10000ml.
[0060] 1.2 Preparation process operation:
[0061] Put the prescribed amount of mannitol in a stainless steel barrel, add 5000ml of injection water to dissolve, add 1‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then use cold injection water to make up the volume to the total amount, adjust the pH value to 6.3 (the pH regulator is a 5% phosphoric acid aqueous solution or a 5% sodium phosphate aqueous solution by mass concentration), filter through a 0.22μm pore size sterilizing filter to the storage tank, and after the semi-finished product is inspected and qualified, it is divided into 2ml tube bottles at 1ml per bottle, and the tube bottles are placed on the plate layer of the freeze drying machine sample room to be freeze-dried.
[0062] 1.3 Freeze drying process:
[0063] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0064] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0°C in 1 hour, keep it warm for 5 hours, and perform primary drying;
[0065] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) for 1 hour and kept warm for 1 hour. The temperature of the plate layer is then raised to 30°C for another 1 hour and kept warm for 3.5 hours (the total freeze-drying time is 16 hours).
[0066] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0067] 1.4 Capping: The freeze-dried and pressed intermediate product is sent to the capping machine for capping.
[0068] 1.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., and put them on a tray and count the number.
[0069] 1.6 Packaging: 10 bottles / box x 100 boxes / piece.
[0070] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 1 are shown in Table 1:
[0071] Table 1 Full test results of batch number 211216 (6 months)
[0072] Inspection items Standard regulations Test results Characteristics Milky white or slightly yellow freeze-dried product Comply with regulations Identification Should comply with regulations Comply with regulations content Should be 90.0-115.0% of the labeled amount 98.62% pH pH 6.0-7.0 pH 6.5 Moisture ≤1.5% 0.8% Visible foreign matter Should comply with regulations Comply with regulations Sterile Should comply with regulations Comply with regulations High molecular weight substances ≤6.0% Not detected Viability assay ≥4.0 5.8 other Should comply with regulations Comply with regulations
[0073] Example 2
[0074] Batch number 211217; production volume 10,000 bottles.
[0075] 2.1 Prescription: 400g of hepatocyte growth hormone; 10mg of L-arginine; 150g of mannitol; add water for injection to 20000ml.
[0076] 2.2 Preparation process operation:
[0077] Put the prescribed amount of mannitol in a stainless steel barrel, add 10000ml of injection water to dissolve, add 1‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then make up the volume to the total amount with cold injection water, adjust the pH value to 6.4 (the pH regulator is a 5% phosphoric acid aqueous solution or a 5% sodium phosphate aqueous solution by mass concentration), filter to the storage tank through a 0.22μm pore size sterilizing filter, and after the semi-finished product is inspected and qualified, it is divided into 5ml tube bottles at 2ml per bottle, and the tube bottles are placed on the plate layer of the freeze-drying machine sample room to be freeze-dried.
[0078] 2.3 Freeze drying process:
[0079] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0080] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0°C in 1 hour, keep it warm for 6 hours, and perform primary drying;
[0081] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) within 1 hour and kept warm for 1.5 hours. The temperature of the plate layer is then raised to 30°C within 1 hour and kept warm for 3.5 hours (the total freeze-drying time is 17.5 hours).
[0082] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0083] 2.4 Capping: The freeze-dried and pressed intermediate product is sent to the capping machine for capping.
[0084] 2.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., and put them on a tray and count the number.
[0085] 2.6 Packaging: 10 bottles / box x 50 boxes / piece.
[0086] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 2 are shown in Table 2:
[0087] Table 2 Full test results of batch number 211217 (6 months)
[0088] Inspection items Standard regulations Test results Characteristics Milky white or slightly yellow freeze-dried product Comply with regulations Identification Should comply with regulations Comply with regulations content Should be 90.0-115.0% of the labeled amount 99.82% pH pH 6.0-7.0 pH 6.8 Moisture ≤1.5% 0.7% Visible foreign matter Should comply with regulations Comply with regulations Sterile Should comply with regulations Comply with regulations High molecular weight substances ≤6.0% Not detected Viability assay ≥4.0 5.7 other Should comply with regulations Comply with regulations
[0089] Example 3
[0090] Batch number 211218; production volume 10,000 bottles.
[0091] 3.1 Prescription: 500g of hepatocyte growth hormone; 10mg of L-arginine; 150g of mannitol; add water for injection to 20000ml.
[0092] 3.2 Preparation process operation process:
[0093] Put the prescribed amount of mannitol in a stainless steel barrel, add 10000ml of injection water to dissolve, add 1‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then make up the volume to the total amount with cold injection water, adjust the pH value to 6.4 (the pH regulator is a 5% phosphoric acid aqueous solution or a 5% sodium phosphate aqueous solution by mass concentration), filter to the storage tank through a 0.22μm pore size sterilizing filter, and after the semi-finished product is inspected and qualified, it is divided into 5ml tube bottles at 2ml per bottle, and the tube bottles are placed on the plate layer of the freeze-drying machine sample room to be freeze-dried.
[0094] 3.3 Freeze drying process:
[0095] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0096] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0°C in 1 hour, keep it warm for 7 hours, and perform primary drying;
[0097] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) for 1 hour and kept warm for 1.5 hours. The temperature of the plate layer is then raised to 30°C for another hour and kept warm for 3.5 hours (the total freeze-drying time is 18.5 hours).
[0098] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0099] 3.4 Capping: The freeze-dried and plugged intermediate product is sent to the capping machine for capping.
[0100] 3.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., and put them on a tray and count the number.
[0101] 3.6 Packaging: 10 bottles / box x 50 boxes / piece.
[0102] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 3 are shown in Table 3:
[0103] Table 3 Full test results of batch number 211218 (6 months)
[0104]
[0105]
[0106] Example 4
[0107] Batch number 211219; production volume 10,000 bottles.
[0108] 4.1 Prescription: 600g of hepatocyte growth hormone; 15mg of L-arginine; 200g of mannitol; add water for injection to 20000ml.
[0109] 4.2 Preparation process operation:
[0110] Put the prescribed amount of mannitol in a stainless steel barrel, add 10000ml of injection water to dissolve, add 1‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then use cold injection water to make up the volume to the total amount, adjust the pH value to 6.3 (the pH regulator is 5% phosphoric acid or 5% sodium phosphate aqueous solution by mass concentration), filter to the storage tank through a 0.22μm pore size sterilizing filter, and after the semi-finished product is inspected and qualified, it is divided into 5ml tube bottles at 2ml per bottle, and the tube bottles are placed on the plate layer of the freeze drying machine sample room to be freeze-dried.
[0111] 4.3 Freeze drying process:
[0112] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0113] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0°C in 1 hour, keep it warm for 8 hours, and perform primary drying;
[0114] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) for 1 hour and kept warm for 1.5 hours. The temperature of the plate layer is then raised to 30°C for another hour and kept warm for 4.5 hours (the total freeze-drying time is 20.5 hours).
[0115] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0116] 4.4 Capping: The freeze-dried and plugged intermediate product is sent to the capping machine for capping.
[0117] 4.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., and put them on a tray and count the number.
[0118] 4.6 Packaging: 10 bottles / box x 50 boxes / piece.
[0119] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 4 are shown in Table 4:
[0120] Table 4 Full test results of batch number 211219 (6 months)
[0121] Inspection items Standard regulations Test results Characteristics Milky white or slightly yellow freeze-dried product Comply with regulations Identification Should comply with regulations Comply with regulations content Should be 90.0-115.0% of the labeled amount 97.89% pH pH 6.0-7.0 pH 6.6 Moisture ≤1.5% 0.7% Visible foreign matter Should comply with regulations Comply with regulations Sterile Should comply with regulations Comply with regulations High molecular weight substances ≤6.0% Not detected Viability assay ≥4.0 5.5 other Should comply with regulations Comply with regulations
[0122] Example 5
[0123] Batch number 2111220; production: 10,000 bottles.
[0124] 5.1 Prescription: 800g of hepatocyte growth hormone; 20mg of L-arginine; 300g of mannitol; add water for injection to 30000ml.
[0125] 5.2 Preparation process operation:
[0126] Put the prescribed amount of mannitol in a stainless steel barrel, add 15000ml of injection water to dissolve, add 2‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then use cold injection water to make up the volume to the total amount, adjust the pH value to 6.9 (the pH regulator is a 5% phosphoric acid aqueous solution or a 5% sodium phosphate aqueous solution by mass concentration), filter through a 0.22μm pore size sterilizing filter to the storage tank, and after the semi-finished product is inspected and qualified, it is divided into 10ml tube bottles at 3ml per bottle, and the tube bottles are placed on the plate layer of the freeze drying machine sample room to be freeze-dried.
[0127] 5.3 Freeze drying process:
[0128] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0129] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0℃ in 1 hour, keep it warm for 8 hours, and perform primary drying.
[0130] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) within 1 hour and kept warm for 2 hours. The temperature of the plate layer is then raised to 30°C within 1 hour and kept warm for 3.5 hours (the total freeze-drying time is 20 hours).
[0131] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0132] 5.4 Capping: The freeze-dried and plugged intermediate product is sent to the capping machine for capping.
[0133] 5.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., and put them on a tray and count the number.
[0134] 5.6 Packaging: 10 bottles / box x 30 boxes / piece.
[0135] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 5 are shown in Table 5:
[0136] Table 5 Full test results of batch number 211220 (6 months)
[0137] Inspection items Standard regulations Test results Characteristics Milky white or slightly yellow freeze-dried product Comply with regulations Identification Should comply with regulations Comply with regulations content Should be 90.0-115.0% of the labeled amount 99.22% pH pH 6.0-7.0 pH 6.7 Moisture ≤1.5% 0.9% Visible foreign matter Should comply with regulations Comply with regulations Sterile Should comply with regulations Comply with regulations High molecular weight substances ≤6.0% Not detected Viability assay ≥4.0 5.9 other Should comply with regulations Comply with regulations
[0138] Example 6
[0139] Batch number 211221; production volume 10,000 bottles.
[0140] 6.1 Prescription: 800g of hepatocyte growth hormone; 20mg of L-arginine; 300g of mannitol; add water for injection to 30000ml.
[0141] 6.2 Preparation process operation:
[0142] Put the prescribed amount of mannitol in a stainless steel barrel, add 15000ml of injection water to dissolve, add 1‰ of the total amount of injection water to activate carbon, boil, keep warm for 15 minutes, filter and remove carbon to obtain solution ①. Add the prescribed amount of L-arginine to solution ①, stir to obtain solution ②. Take the prescribed amount of hepatocyte growth factor, add 1000ml of cold injection water below 25℃ to dissolve to obtain solution ③. Slowly pour solution ② and solution ③ into the batching tank, and then use cold injection water to make up the volume to the total amount, adjust the pH value to 6.0-7.0 (the pH regulator is a 5% phosphoric acid aqueous solution or a 5% sodium phosphate aqueous solution by mass concentration), filter through a 0.22μm pore size sterilizing filter to the storage tank, and after the semi-finished product is inspected and qualified, it is divided into 10ml tube bottles at 3ml per bottle, and the tube bottles are placed on the plate layer of the freeze drying machine sample room to wait for freeze drying.
[0143] 6.3 Freeze drying process:
[0144] (1) Prefreezing: First, the condenser temperature of the freeze dryer is pre-lowered to below -45°C. After the semi-finished product enters the box, the plate layer temperature is quickly reduced to below -35°C within 1 hour and maintained at a low temperature for 2.5 hours;
[0145] (2) Primary drying: Turn on the vacuum pump, maintain the vacuum degree below 10Pa, raise the temperature of the board layer to 0℃ in 1 hour, keep it warm for 6 hours, and perform primary drying.
[0146] (3) Secondary drying: After the product is dried once, the temperature of the plate layer is raised to 12°C (the vacuum degree is controlled at 10-15 Pa) within 1 hour and kept warm for 2 hours. The temperature of the plate layer is then raised to 30°C within 1 hour and kept warm for 3.5 hours (the total freeze-drying time is 18 hours).
[0147] (4) During the freeze-drying process, check the plate layer temperature, product temperature, condenser temperature, etc. After the freeze-drying is completed, perform hydraulic plugging.
[0148] 6.4 Capping: Send the freeze-dried and pressed intermediate product to the capping machine for capping.
[0149] 6.5 Visual inspection: Check each bottle one by one. Pick out the bottles with large differences in filling volume, loose caps, warped plugs, foreign objects in the medicine, etc., place them on a tray and count the number.
[0150] 6.6 Packaging: 10 bottles / box x 30 boxes / piece.
[0151] The test results of the claims of the preparation containing hepatocyte growth promoting factor prepared in Example 6 are shown in Table 6:
[0152] Table 6 Full test results of batch number 211221 (6 months)
[0153] Inspection items Standard regulations Test results Characteristics Milky white or slightly yellow freeze-dried product Comply with regulations Identification Should comply with regulations Comply with regulations content Should be 90.0-115.0% of the labeled amount 98.26% pH pH 6.0-7.0 pH 6.6 Moisture ≤1.5% 0.9% Visible foreign matter Should comply with regulations Comply with regulations Sterile Should comply with regulations Comply with regulations High molecular weight substances ≤6.0% Not detected Viability assay ≥4.0 5.5 other Should comply with regulations Comply with regulations
[0154] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A preparation containing hepatocyte growth promoting factor, comprising the following ingredients: hepatocyte growth promoting factor and L-arginine.
2. The preparation according to claim 1, characterized in that The preparation comprises the following components in parts by weight: 200-800 parts of hepatocyte growth promoting factor and 0.005-0.02 parts of L-arginine.
3. The preparation according to claim 1 or 2, characterized in that The formulation also includes excipients and water; Preferably, the weight portion of the excipient in the preparation is 100-300 parts; Preferably, the weight portion of water in the preparation is 10000-30000 parts; Preferably, the excipient is mannitol; Preferably, the water is water for injection.
4. The method for preparing the preparation according to any one of claims 1 to 3 comprises the following steps: (1) heating a mixed solution containing an excipient, activated carbon and water, and filtering and removing carbon after heating is completed to obtain a first solution; (2) Mixing the first solution, L-arginine and the aqueous solution containing hepatocyte growth promoting hormone to obtain a mixed solution, adjusting the pH of the mixed solution, filtering to obtain a semi-finished product, and freeze-drying the semi-finished product to obtain a preparation containing hepatocyte growth promoting hormone.
5. The preparation method according to claim 4, characterized in that: In step (1), the weight ratio of the activated carbon to the excipient is 1:(8-12); And / or, in step (1), the weight ratio of the excipient to water is 1:(100-300); And / or, in step (1), the heating is heating the mixed solution to boiling and maintaining boiling for 10-20 minutes.
6. The preparation method according to claim 4 or 5, characterized in that: In step (2), the water temperature of the aqueous solution containing hepatocyte growth promoting factor is ≤25°C, preferably 2-10°C; And / or, in step (2), the weight ratio of the hepatocyte growth factor to water in the aqueous solution containing the hepatocyte growth factor is (2-3):
100.
7. The preparation method according to any one of claims 4 to 6, characterized in that: The pH value of the mixed solution is adjusted to 6.0-7.0; Preferably, phosphoric acid and / or sodium phosphate are used to adjust the pH of the mixed solution; Preferably, a phosphoric acid aqueous solution with a mass concentration of 3% to 10% is used to adjust the pH of the mixed solution; Preferably, a sodium phosphate aqueous solution with a mass concentration of 3% to 10% is used to adjust the pH of the mixed solution; And / or, in step (2), the filtration is performed using a sterilizing filter; Preferably, the pore size of the sterilizing filter is 0.2-0.3 μm.
8. The preparation method according to any one of claims 4 to 7, characterized in that: The freeze drying comprises pre-freezing at a temperature of ≤-35°C, performing primary drying at a temperature of 5 to -5°C after the pre-freezing is completed, and performing secondary drying at a temperature of 12°C to 30°C after the primary drying is completed.
9. The preparation method according to claim 8, characterized in that: The pre-freezing time is 2-5h; And / or, the vacuum degree of the primary drying is ≤10Pa; And / or, the primary drying time is 5-8h; And / or, the secondary drying includes two stages, the drying temperature of the first stage is 10-15°C; preferably, the vacuum degree of the first stage is 10-15Pa; further preferably, the drying time of the first stage is 1-2h; Preferably, the drying temperature of the second stage of the secondary drying is 25-35°C; more preferably, the vacuum degree of the second stage is 10-15Pa; further preferably, the drying time of the second stage is 3-5h; Preferably, the heating time between two adjacent drying processes is 50-70 minutes.
10. The preparation method according to any one of claims 4 to 9, characterized in that: The freeze drying is carried out using a freeze dryer. Preferably, before the semi-finished product enters the freeze dryer, the temperature of the freeze dryer is pre-lowered to ≤-45°C; Preferably, after the semi-finished product enters the freeze dryer, the plate temperature of the freeze dryer is reduced to ≤-35°C within 30-60 minutes.
